MD2335F2 - Hidrat cristalin de hidroclorura de 6-hidroxi-3-(4-[2-(piperidina-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obtinere, compozitie farmaceutica care il contine si utilizarea pentru inhibarea starilor patologice si activarea colinacetiltransferazei - Google Patents

Hidrat cristalin de hidroclorura de 6-hidroxi-3-(4-[2-(piperidina-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obtinere, compozitie farmaceutica care il contine si utilizarea pentru inhibarea starilor patologice si activarea colinacetiltransferazei Download PDF

Info

Publication number
MD2335F2
MD2335F2 MDA20000161A MD20000161A MD2335F2 MD 2335 F2 MD2335 F2 MD 2335F2 MD A20000161 A MDA20000161 A MD A20000161A MD 20000161 A MD20000161 A MD 20000161A MD 2335 F2 MD2335 F2 MD 2335F2
Authority
MD
Moldova
Prior art keywords
benzo
piperidine
ethoxy
hydroxy
methoxyphenyl
Prior art date
Application number
MDA20000161A
Other languages
English (en)
Other versions
MD20000161A (ro
MD2335G2 (ro
Inventor
Julie Kay Bush
Preston Charles Conrad
Merlyn Gerard Flom
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MD20000161A publication Critical patent/MD20000161A/ro
Publication of MD2335F2 publication Critical patent/MD2335F2/ro
Publication of MD2335G2 publication Critical patent/MD2335G2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
MDA20000161A 1999-07-29 2000-07-28 Hidrat cristalin de hidroclorură de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obţinere, compoziţie farmaceutică care îl conţine şi utilizarea pentru inhibarea stărilor patologice şi activarea colinacetiltransferazei MD2335G2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14618499P 1999-07-29 1999-07-29
US14764299P 1999-08-06 1999-08-06
US14982099P 1999-08-19 1999-08-19

Publications (3)

Publication Number Publication Date
MD20000161A MD20000161A (ro) 2001-04-30
MD2335F2 true MD2335F2 (ro) 2003-12-31
MD2335G2 MD2335G2 (ro) 2004-06-30

Family

ID=27386367

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20000161A MD2335G2 (ro) 1999-07-29 2000-07-28 Hidrat cristalin de hidroclorură de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obţinere, compoziţie farmaceutică care îl conţine şi utilizarea pentru inhibarea stărilor patologice şi activarea colinacetiltransferazei

Country Status (44)

Country Link
EP (1) EP1204655B1 (ro)
JP (1) JP2001048880A (ro)
KR (1) KR100733094B1 (ro)
CN (1) CN1138771C (ro)
AR (1) AR029176A1 (ro)
AT (2) ATE251151T1 (ro)
AU (2) AU6335500A (ro)
BE (1) BE1013410A3 (ro)
BR (1) BR0003211A (ro)
CA (1) CA2314685C (ro)
CO (1) CO5180572A1 (ro)
CZ (1) CZ300356B6 (ro)
DE (2) DE60005693T2 (ro)
DK (1) DK176771B1 (ro)
EG (1) EG24196A (ro)
ES (1) ES2208384T3 (ro)
FI (1) FI20001721A7 (ro)
FR (1) FR2798384B1 (ro)
GB (1) GB2352716A (ro)
GR (1) GR20000100264A (ro)
HR (1) HRP20000502B1 (ro)
HU (1) HUP0003005A2 (ro)
ID (1) ID26679A (ro)
IL (1) IL137552A (ro)
IT (1) IT1318659B1 (ro)
LT (1) LT4789B (ro)
LU (1) LU90616B1 (ro)
LV (1) LV12733B (ro)
MD (1) MD2335G2 (ro)
MX (1) MXPA00007462A (ro)
MY (1) MY120393A (ro)
NL (1) NL1015822C2 (ro)
NO (1) NO325594B1 (ro)
NZ (1) NZ506045A (ro)
PE (1) PE20010383A1 (ro)
PL (1) PL341748A1 (ro)
PT (1) PT102501A (ro)
SE (1) SE0002793L (ro)
SG (1) SG90737A1 (ro)
SI (1) SI20427B (ro)
SV (1) SV2002000134A (ro)
TR (1) TR200002205A2 (ro)
TW (1) TWI271403B (ro)
WO (1) WO2001009115A2 (ro)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005200809B2 (en) * 2000-05-08 2006-05-11 Eli Lilly And Company Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
IL152699A0 (en) * 2000-05-08 2003-06-24 Lilly Co Eli STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO [b] THIOPHENE AND SALTS THEREOF
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
UA76124C2 (en) * 2000-10-20 2006-07-17 Lilly Co Eli A crystal form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride, pharmaceutical composition and a method for producing
US6921827B2 (en) 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
WO2006019835A1 (en) * 2004-07-22 2006-02-23 Eli Lilly And Company A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt
EP2425845A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
WO2006088648A1 (en) * 2005-02-11 2006-08-24 Eli Lilly And Company Compositions and methods for treating dyslipidemia
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
CN113325183B (zh) * 2021-06-01 2022-11-15 中国医学科学院北京协和医院 一种用于鉴别诊断em/fem的试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR003930A1 (es) * 1995-02-28 1998-09-30 Lilly Co Eli Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Also Published As

Publication number Publication date
SE0002793L (sv) 2001-01-30
PT102501A (pt) 2001-01-31
LT2000075A (lt) 2001-02-26
ATE251151T1 (de) 2003-10-15
BR0003211A (pt) 2001-03-13
WO2001009115A2 (en) 2001-02-08
LV12733B (lv) 2002-02-20
NL1015822A1 (nl) 2001-01-30
DK200001150A (da) 2001-01-30
SI20427B (sl) 2009-04-30
IL137552A (en) 2009-06-15
LU90616B1 (fr) 2007-06-08
MD20000161A (ro) 2001-04-30
LT4789B (lt) 2001-05-25
HU0003005D0 (en) 2000-10-28
MD2335G2 (ro) 2004-06-30
CN1283622A (zh) 2001-02-14
GB2352716A (en) 2001-02-07
TR200002205A2 (tr) 2001-03-21
SG90737A1 (en) 2002-08-20
MXPA00007462A (es) 2002-06-04
WO2001009115A3 (en) 2001-08-16
SV2002000134A (es) 2002-06-07
KR100733094B1 (ko) 2007-06-27
EP1204655B1 (en) 2003-10-01
NO20003876L (no) 2001-01-30
FI20001721L (fi) 2001-01-30
CO5180572A1 (es) 2002-07-30
NZ506045A (en) 2002-02-01
HUP0003005A2 (hu) 2002-04-29
NL1015822C2 (nl) 2004-08-04
MY120393A (en) 2005-10-31
PL341748A1 (en) 2001-02-12
FI20001721A7 (fi) 2001-01-30
FI20001721A0 (fi) 2000-07-28
NO325594B1 (no) 2008-06-23
ITMI20001758A0 (it) 2000-07-28
CN1138771C (zh) 2004-02-18
FR2798384B1 (fr) 2004-09-24
ITMI20001758A1 (it) 2002-01-28
HRP20000502B1 (en) 2008-04-30
IT1318659B1 (it) 2003-08-27
LV12733A (lv) 2001-10-20
HRP20000502A2 (en) 2001-06-30
DK176771B1 (da) 2009-08-03
AU4891100A (en) 2001-02-01
BE1013410A3 (fr) 2001-12-04
HK1034962A1 (en) 2001-11-09
TWI271403B (en) 2007-01-21
EP1204655A2 (en) 2002-05-15
GB0018636D0 (en) 2000-09-13
DE10036855A1 (de) 2001-03-22
KR20010049911A (ko) 2001-06-15
DE60005693T2 (de) 2004-07-29
FR2798384A1 (fr) 2001-03-16
GR20000100264A (el) 2001-03-30
ID26679A (id) 2001-02-01
DE60005693D1 (de) 2003-11-06
CA2314685A1 (en) 2001-01-29
IE20000604A1 (en) 2001-04-04
SI20427A (sl) 2001-06-30
JP2001048880A (ja) 2001-02-20
AR029176A1 (es) 2003-06-18
ES2208384T3 (es) 2004-06-16
CZ300356B6 (cs) 2009-04-29
NO20003876D0 (no) 2000-07-28
AT502317A1 (de) 2007-02-15
AU779559B2 (en) 2005-01-27
IL137552A0 (en) 2001-07-24
AU6335500A (en) 2001-02-19
SE0002793D0 (sv) 2000-07-28
CZ20002717A3 (en) 2001-05-16
EG24196A (en) 2008-10-14
PE20010383A1 (es) 2001-04-05
CA2314685C (en) 2009-10-20

Similar Documents

Publication Publication Date Title
MD2335F2 (ro) Hidrat cristalin de hidroclorura de 6-hidroxi-3-(4-[2-(piperidina-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obtinere, compozitie farmaceutica care il contine si utilizarea pentru inhibarea starilor patologice si activarea colinacetiltransferazei
PL344861A1 (en) Trazinic angiogenesis inhibitiors
EP1322619A4 (en) ISOCHINOLINONES AS POTASSIUM CHANNEL INHIBITORS
BG104779A (en) Inhibitors of phospholipase enzymes
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
MD2336G2 (ro) Hidrat cristalin de hidroclorură de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obţinere , compoziţie farmaceutică care îl conţine şi utilizarea pentru inhibarea stărilor patologice şi activarea colinacetiltransferazei
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
EA200300491A1 (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗО[b]ТИОФЕНА
RU2000120574A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
RU2000120575A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
US9708305B2 (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases
AU1047002A (en) 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees